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Chapter 1 
 
1. Background 
 
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is 
characterized by chronic relapsing intestinal inflammation. It is a worldwide health-care problem 
with increasing incidence. It is thought that IBD results from an aberrant and continuing immune 
response to the microbes in the gut, catalyzed by the genetic susceptibility of the individual.  
Although the etiology of IBD remains largely unknown, it involves a complex interaction between 
the genetic, environmental or microbial factors and the immune responses. Recently, most rapid 
progress has been made in the genetic study of gut inflammation.  
 However, the fact that genetic factors account for only a portion of overall disease variance 
indicates that microbial and environmental factors may interact with genetic elements in the 
pathogenesis of IBD. Meanwhile, the adaptive immune response has been classically considered to 
play a major role in the pathogenesis of IBD, although new studies in immunology and genetics 
have clarified that the innate immune response maintains the same importance in inducing gut 
inflammation.   
 
Genetics  
Over the past decades, there have been huge advances in our understanding of genetic contributions 
to IBD
1
. This is due to the technological advances in DNA analysis and sequencing and the use of 
huge multinational databases
2
. Advances in genetic testing and analyzing technologies have allowed 
for the completion of many genome-wide association studies (GWAS) which identify single 
nucleotide polymorphisms (SNPs). Recent studies have brought the number of IBD-associated gene 
loci to 163, of which 110 are associated with both diseases, 30 CD specific and 23 UC specific
3
. 
Studies of gene loci shared by UC and CD may provide new way to find their common 
pathogenesis. 
The IBD genetic research began in 2001 with the discovery of  NOD2 (nucleotide-
bindingoligomerization domaincontaining 2), the first susceptibility gene for CD
4
. The NOD2 gene 
codes for a protein that was originally described as an intracellular receptor recognizing the 
muramyl dipeptide (MDP), a conserved motif present in peptidoglycan from both Gram-positive 
and -negative bacteria
5
. MDP stimulation induces autophagy which controls bacterial replication 
and antigen presentation
 6,7
, and modulates both innate and adaptive immune responses
8
 
9
. 
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Genetic analyses have shown an indispensable role for autophagy in immune responses in IBD, and 
reported two autophagy-related genes named ATG16L1and IRGM
10,11
. Autophagy is a degradation 
mechanism originally implicated in the recycling of damaged proteins and provision of amino acids 
during nutrient starvation.
4
 More recent studies have shown that the process is also involved in the 
degradationof intracellular pathogens and resistance against infection
12
. ATG16L1 is essential for all 
forms of autophagy, and the coding mutation T300A is associated with an increased risk of CD. 
IRGM belongs to the p47immunity-related GTPase family. CD-associated polymorphisms in IRGM 
lead to reduced protein expression. 
Epithelial cells and dendritic cells containing ATG16L1 and NOD2 variants show defects in 
antibacterial autophagy
7,13
. GWAS have also pointed out a significant associatiom between IBD and 
the IL23R gene 
14
. The IL23R gene encodes a subunit of the receptor for the pro-inflammatory 
cytokine interleukin (IL)-23, a peptide involved in the generation of Th17 cells. The Th17 and IL-
23 pathway is well established in the pathogenesis of IBD, with susceptibility gene loci IL23R, 
IL12B, JAK2, and STAT3  having been identified in both UC and CD
15,16
. Variants in IL12B, which 
encodes the p40 subunit of IL-12 and IL-23, have been associated with IBD and other immune 
disorders. Defects in the function of IL-10 have also been associated with CD and UC
17
. Other 
susceptibility genes that regulate immune function include CARD9,IL1R2, REL, SMAD3 and 
PRDM1. The expanding numberof susceptibility gene loci described in IBD indicates that genetic 
influences are critical components of the disease pathogenesis; however the susceptibility loci 
mentioned above account for only 20%-25% of the heritability. Indeed, more recent theories 
emphasize the role of epigenetics, which alter cellular features through specific DNA methylation 
patterns and it has been first of all identified to contribute to asthma
18
. Direct or indirect influence 
on epigenetic patterns in pertinent cell types may explain the gap in IBD heritability left after 
GWAS studies. The genetic susceptibility of a human remains constant during lifetime. In contrast, 
epigenetic changes occur permanently, induced by microbiota components or directly by 
environmental triggers 
18
. These new insights into genetics and heritability of IBD implicate that 
future explorations of gene-gene interactions, gene-pathway interaction and gene-environment 
interactions are likely to give us more insights into IBD pathogenesis than finding new rare variants. 
 
Environment 
There is no doubt that environmental factors play an important role in the pathogenesis of IBD. A 
large number of environmental factors are considered risk factors for IBD, including smoking, diet, 
drugs, geography, socialstress, and psychological element
18
. So far  in addition to familial 
aggregation, which is the most important IBD risk factor, only tobacco smoking and appendectomy 
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have been demonstrated to be strongly associated with IBD incidence
3,5
.  The contribution of other 
potential environmental risk factors, proposed as important in IBD predisposition (including oral 
contraceptives and diet), has not yet been demonstrated because of discordant results
6,7
. An 
emerging and interesting theory is the “hygiene hypothesis, which correlates the epidemiological 
rise in IBD incidence over the 20th century, both in developed and developing countries, with the 
improvement in general hygienic conditions (i.e. free access to clean water, smaller family size, 
etc.)
20,21
. This theory asserts that exposure to poor hygiene or infections during childhood can 
protect from developing IBD or other kind of autoimmune and allergic diseases later in life
23,24
.  
Moreover, several epidemiological studies suggested a role of perinatal or early life events in the 
etiology of IBD
10,11,12
, such as non-specific (gastroenteritis and other non-specific infections) and 
specific (vaccines, passive smoking) exposures.  A possible explanation is that a decreased 
prevalence of infections during childhood could lead to a major individual susceptibility in 
developing IBD later in life.  However, there are no definitive data demonstrating a final role of 
hygiene in IBD development. Understanding the role of environmental factors is important not only 
for the possible preventive interventions in genetically predisposed individuals, but also to offer a 
better disease care to those already suffering with IBD.  
 
Microbial factors 
The whole human gut microbiome consists of approximately 1150 bacterial species, with each 
individual host having roughly 160 species
19
. Gut microbiome is established within the first 2 wk of 
life and then usually remains remarkably stable thereafter. Recent studies have shown disease 
associations with dysbiosis or abnormal compositions of the gut microbiota 
20, 21,22,23
, finding a 
significantly reduced biodiversity in faecal microbiome in IBD patients compared to that in healthy 
controls
24
. 
Dysbiosis includes  increases in bacterial numbers, a decreased bacterial biodiversity,a increased 
abundance of the phyla Proteobacteria and Bacteroidetes, and a decreased abundance of 
Firmicutes
25,26
. Changes to the composition of the microbiome and its interaction with the immune 
system play a crucial role in the pathogenesis of CD and UC. Genetic susceptibility leads to a 
dysregulation of the mucosal immune system that result in excessive immunologic responses to 
normal flora, however in addition also an imbalance exists in the composition of the microbiota 
elicits a pathologic response from the normal mucosal immune system
 27
. In healthy intestine, the 
Firmicutes and Bacteroidetes phyla predominate,  and contribute to the production of epithelial 
metabolic substrates. In contrast, the microbiota is characterized by a relative lack of Firmicutes and 
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Bacteroidetes, and an over-representation of enterobacteria in CD; whereas in UC it has been 
reported a reduction in Clostridium spp. and an increase in Escherichiacoli (E. coli) 
28, 29
. 
Future research needs to further clarify whether the intestinal dysbiosis in IBD patients is a cause or 
a result of intestinal inflammation , it is likely that such alterations in bacterial populations has a 
knock on effect on gut immune system; perhaps disrupting the delicate balance that is maintained in 
the healthy gut and further contributing to pathology. 
 
Immunological factors 
Most studies in the last two decades have focused on the role of abnormal adaptive immune 
responses in the pathogenesis of IBD. 
The focus on the adaptive immune response has ultimately led to the notion that the two main types 
of IBD represent clearly distinct forms of gut inflammation: CD has long been considered to be 
driven by a Th1 response and UC has been associated with a non-conventional Th2 response
30,31
. 
The newly described Th17 cells are also involved in the gut inflammatory response in IBD
32
. 
However, immunological studies have recently focused on the mucosal innate immune responses, 
such as epithelial barrier integrity, innate microbial sensing, autophagy and unfolded protein 
response. 
 
 
Innate immunity 
The innate immune response represents the first line of defense against pathogens and it is initiated 
by the recognition of microbial antigens by pattern recognition receptors including toll-like 
receptors (TLRs) on the cell surface and NOD lik ereceptors in the cytoplasm
33
. Recent studies have 
found that the behavior of the cells mediating innate immunity and the expression and function of 
both TLRs and NOD proteins are altered signicantly in individuals with IBD. GWAS reveal that 
the NOD2 muta- tions most commonly associated with CD induce a defective ability of the gut to 
respond to LPS, and this defect may contribute to disease susceptibility 
34 
. Although the functional 
role of NOD2 mutations is still controversial, available evidence suggests that they represent loss-
of- function mutations that lead to reduced activation of NF- κB35.This lacking response might 
result in reduced antibacterial agent production and pathogenic microbial invasion
36
. Other studies 
suggest that the loss of function of NOD2 may result in the lack of inhibition of TLR2 stimulation, 
leading to activation of inflammatory pathways and excessive Th-1 responses
37
. Furthermore, 
NOD2 also contributes to immune tolerance. These effects are impaired in cells from patients with 
NOD2 mutation 3020insC
38
. IL-23 is a key cytokine both in innate and adaptive immunity and 
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possesses a central role in driving early responses against microbes. IL23R polymorphisms have 
been associated with both CD and UC, suggesting that IL-23 may represent a shared inflammatory 
molecule in chronic intestinal inflammation. Recent studies have shown that, besides its activity on 
Th17 cells, IL-23 can also act on cells of the innate immune system. IL-23 has been shown to 
induce Th17 cytokine production by innate lymphoid cells (ILCs) that share the phenotype of 
lymphoid tissue-induced cells
39
. CD has also been associated with ATG16L1 and IRGM genes, 
which are involved in autophagy. Recent studies have shown that autophagy is also involved in the 
degradationof intracellular pathogens. In patients with mutations in NOD2 or Atg16L1 it has been 
described decreased bacterial handling. Moreover, also dysregulation of the unfolded protein, which 
is linked to autophagy and innate immunity response, may contribute to IBD pathogenesis. This 
response is induced by endoplasmic reticulum stress and induces apoptotic cell death, contribuiting 
to IBD pathogenesis
40
. In addition, defective epithelial barrier and increased intestinal permeability 
have been observed in IBD patients
41
. The first physical barrier against intestinal bacteria and food 
antigens e is represented by the mucous layer that covers the intestinal epithelium and it is 
important in the prevention of bacterial invasion and intestinal inflammation
 42
. The second line of 
defense is formed by the intestinal epithelium, which form a physical barrier against bacteria, and 
can secrete different antimirobial peptides. Defective expression of antimicrobial peptides has been 
observed in patients with CD
43
.  
 
Adaptive immunity  
As opposed to the innate immune response, the adaptive immunity is highly specific, often takes 
several days to respond and depends on the type and number of T cells. Th1 cells, induced by IL 12, 
produce a high amount of IFN-γ, whereas Th2 cells release IL-4, IL-5 and IL-1344. An abnormal 
Th1 immune response is thought to cause intestinal inflammation in CD, and it has been observed 
that mucosal T cells from CD patients produce higher amounts of IL-2 and IFN-γ than T cells from 
UC patients or controls
45
. Whereas in UC it has been shown that  a typical NK T cells release higher 
amounts of the Th2 cytokine IL-13 than T cells from controls or CD patients 
46,47
.Therefore, CD has 
been thought to be characterized by a Th1 immune response, while UC has been considered as a 
Th2-mediated disease
48
. Although, there have also been different observations about mucosal Th1 
and Th2 cytokines in IBD. Both UC and CD biopsies cultured in vitro release high and comparable 
amounts of IFN-γ49. Lower levels of IL-13 are found in the colonic mucosa of UC patients 
compared to those in CD patients and subjects of the control group. Collectively, these data should 
lead us to reconsider the Th1/Th2 paradigm in CD and UC
48
. 
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Th17 cells are a T cell subset characterized by the production of large amounts of IL-17A, IL-17F, 
IL-21 and IL-22. They are induced by a combination of IL-6 and transforming growth factor (TGF)-
β, and their ex- pansion is promoted by IL-2350. High transcript levels of IL-17A have been 
detected both in CD and UC mucosa in comparison to normal gut
51,52
. Moreover, the inflamed IBD 
mucosa cultured in vitro produces higher levels of IL-17A than the control
45
. Furthermore, Th17 
cells are an important source of IL-21, an IL-2-related cytokine which is up-regulated in inflamed 
IBD mucosa.
 53
  
  
10 
 
1.2 The main aims of this PhD thesis are: 
The main aim of this PhD thesis are: 
 Deepen the knowledge of IBD pathogenesis: 
 Investigate clinical and functional implication of impaired autophagy in 
inflammatory bowel disease  
 Study the relation between the exposure to environmental factors and the risk to 
develop UC and CD in a cohort of pediatric patients in Southern Italy. 
 Correlate serum levels of hepcdin, a protein that controls the amount of iron entering 
the blood circulation,with disease activity, inflammatory markers, and iron 
absorption in patients affected by paediatric IBD 
 Dissection of the cross-talk between the different mucosal compartments to evaluate 
the cytokine production profile and the activation status of both lamina propria and 
epithelium cell compartments through an ex vivo analysis of colon biopsies obtained 
from pediatric patients with IBD. 
  Investigate genetic susceptibility in inflammatory bowel disease 
 Clarify the molecular basis of an early onset ulcerative colitis in an 18-mo-old 
affected child with consanguineous parents. 
 Conduct a case-control association analysis between the common CB2-Q63R 
functional variant of the cannabinoid receptor 2 and IBD in a pediatric cohort of 
children and evaluate possible correlations between the CB2-Q63R variant and the 
clinical features . 
 Describe peculiar clinical features  of pediatric inflammatory bowel disese 
 Investigate prevalence and disease course of paediatric IBD patients presenting with 
pancreatitisin a multicenter study. 
 Evaluate by endoscopy and histology the prevalence of periappendiceal 
inflammation in children affected by UC.  
 Study the occurrence and the natural history of C. difficile infection in a multicenter 
pediatric study. 
 
 
 Propose new therapeutic strategies for the treatment of IBD. 
 Analyze the effects of a mixture of 3 Bifidobacterium strains (B. longum, B. breve, 
B. infantis), on the phenotype and on antigen processing of monocyte-derived DCs 
in a pediatric cohort with IBD. 
11 
 
 Evaluate the efficacy of a cow’s milk protein  elimination diet on induction and 
maintenance of remission in UC and define the associationwith atopy in children 
with UC 
 Provide a consensus based recommendations specifically for paediatric 
gastroenterologists treating children with IBD regarding the use of biosimilars.  
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Chapter 2 
 
2.1 New insights in the pathogenesis of Inflammatory Bowel disease 
 
2.1.1 Impaired autophagy leads to abnormal dendritic cell-epithelial cell interactions.  
 
Genome wide association studies have linked SNP in various autophagy related genes to the 
occurrence of Crohn's disease.
1-3
 Autophagy is a degradation mechanism originallyimplicated in the 
recycling of damaged proteins and provision of amino acids during nutrient starvation.
4
 More recent 
studies have shown that the process is also involved in the degradationof intracellular pathogens 
such as Salmonella enterica and Mycobacterium tuberculosis.
5-6
 The polymorphisms associated 
with Crohn's disease result in decreased levels of autophagy,leading to decreased bacterial handling. 
Additionally, ATG16L1 hypomorphic animals display Paneth cell abnormalities, resulting in a 
deceased release of antimicrobial peptides into the intestinal lumen.
7
 The current theory of how 
autophagy-related SNP contribute to Crohn's disease is therefore based on an indirect effect, where 
a decrease in bacterial handling results in an altered microbiome.
8-9
 
In addition to the function of autophagy in innate immunity, we have recently shown that autophagy 
also modulates adaptive responses through regulation of DC–T cell interactions.10 When autophagy 
levels are insufficient, these interactions are hyperstable, resulting in increased activation of the 
adaptive immune system. Whether autophagy is also involved in the regulation of other cellular 
interactions has not been studied thus far. 
A particular type cellular interaction which is interesting in the context of Crohn's disease is that 
between the intestinal epithelium and local DC. It has been shown that DC can sample luminal 
antigens by extending protrusions in between epithe-lial cells and into the lumen.
11
 During this 
process, epithelial barrier function is maintained because the DC form tight junctions with the 
surrounding epithelial cells.
12-13
 The proper ratio between tight junction formation and release is 
important for the efficacy of antigen sampling. Additionally, since tight junction protein bonds have 
been implicated in the activation status of DC, the regulation of tight junction may also influence 
the induction of tolerance versus immunity by DC.
14
 We hypothesized that autophagy is involved in 
the regulation of DC–epithelial interactions, and thereby influences the ability to sample luminal 
antigens and the maintenance of a tolerogenic status. 
In the intestine, DC form protrusions in between the epithelial  layer, while maintaining barrier 
function through the continuous formation of tight junction like structures with epithelial cells. We 
started our investigations by determining whether the level of autophagy regulates the expression of 
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tight   junction proteins. Intestinal epithelial cells and dendritic cells express various tight junction 
proteins, including ZO-1 and occludin. Upon activation of autophagy using the mTOR inhibitor 
rapamycin,  occludin levels were decreased in both cells tipe, whereas levels of ZO-1 did not 
change. 
 Previous studies implicated E-cadherin in formation of intestinal tight junctions. We therefore 
determined the levels of E-cadherin expression in the presence and absence of autophagy. 
Rapamycin stimulation resulted in decreased protein levels of E-cadherin, both in epithelial cells 
and DC. The decreased expression of E-cadherin after activation of  autophagy suggests that 
autophagy functions as a degradation  mechanism for this protein. To further confirm this, we  
performed colocalization analysis with confocal microscope between E-cadherin and the 
autophagosomal marker LC3 in cultured DC. However, after activation of autophagy, the number of 
co-localizing spots was significantly enhanced, supporting the hypothesis that autophagy is 
involved in E-cadherin degradation.Finally to confirm the importance of E-cadherin in DC–
epithelial cell interactions, we co-cultured these two cell types and studied the localization of E-
cadherin in the resulting cell clusters. Indeed, E-cadherin was found to localize to the site of the 
interactions. Interestingly, an accumulation was seen at the outer edges of the interaction, 
suggesting a role in “sealing” the interaction from the environment.  
 The data described above indicate that autophagy is involved in the degradation of tight junction 
proteins. As these proteins play an important role in the regulation of cell–cell interaction, we 
hypothesized that autophagy also regulates DC- epithelial interactions. 
To test this,we used a model system for the DC sampling of luminal antigens which has been 
described previously.
13
 Decreased autophagy resulted in a decreased number of protrusions whether 
autophagy was knocked down in DC, epithelial cells or both. Since formation of these protrusions is 
important for  antigen sampling, decreased protrusions might lead to decreased antigen uptake by 
DC. To test this, fluorescently labeled E. coli derived particles were applied to the apical side of the 
transwell culture system. Indeed, when autophagy was knocked down in DC, the amount of antigen 
taken up by these cells was decreased . When autophagy was decreased in epithelial cells, antigen 
uptake was decreased in the cultures using Caco-2 cells. To mimic the physiological situation in 
patients, in whom autophagy defects are present in all cell types, both DC and epithelial cells were 
treated with siRNA. Under these conditions, the formation of protrusions was impaired and the 
level of antigen uptake by DC was reduced, indicating that the net outcome of the opposing effects 
is a decrease in antigen sampling.  
In summary, these data show that decreased levels of autophagy result in decreased antigen 
sampling of intestinal DC, but increased capacity to activate the adaptive immune system. Since 
19 
 
impaired innate immunity but increased adaptive immunity is exactly the phenotype seen in 
Crohn'sdisease patients, this mechanism may be contributing to the inflammation seen in patients 
carrying mutations in the autophagy pathway. 
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2.1.2 T300A variant of autophagy ATG16L1 gene is associated with decreased antigen sampling 
and processing by dendritic cells in paediatric Crohn’s disease. 
 
We have previously shown that if autophagy is impaired, DC form hyperstable interactions with T 
cells
15
, and their antigen sampling through epithelial cell monolayers is greatly decreased
16
. In these 
studies, autophagy was inhibited by the use of siRNA or by pharmacological inhibitors, and though 
very informative, it remains an indirect reflection of the physiological condition in subjects carrying 
the risk allele of the ATG16L1. 
In the present study we aimed to investigate the physiological relevance of an impaired autophagy 
machinery for human disease by analysing phenotype and function of DC obtained from CD 
patients carrying the risk allele of ATG16L1 gene. In particular, since very little is known on the 
role of autophagy in paediatric inflammatory bowel disease (IBD), we have investigated the 
phenotype and antigen sampling capacity of DC in children carrying the ATG16L1 T300A variant. 
In this study we demonstrate that the monocyte-derived DC from paediatric patients with Crohn’s 
disease carrying the ATG16L1 polymorphism T300A, associated with a defective autophagy, are 
impaired in proper antigen sampling and processing. We found a marked reduction of bacteria 
particle localization in DC from CD children with the ATG16L1risk variant compared to DC of 
children with ATG16L1 wild type variant, indicating an impairment of particulate antigen sampling. 
DC from CD patients with ATG16L1risk variant were also impaired in processing of soluble 
antigen, as shown by reduced intracellular degradation of ovalbumin. Furthermore, we found that 
DC from the risk group almost completely failed in up-regulating the HLA-DR and CD86, the early 
activation markers, after a brief incubation with particulate or soluble antigens. 
Interestingly, the DC from children that were heterozygous for ATG16L1T300A polymorphism 
were hampered in bacteria particles, but not ovalbumin, phagocytosis. Moreover, DC from the 
ATG16L1 heterozygous group did not upregulate HLA-DR on the surface membrane after exposure 
to bacteria particles or to ovalbumin. The impairment of het DC functionality suggested a dose 
dependent effect of the T300A allele that has never been described, if excepted only one study that 
reported a dose effect of this allele with CD risk.
17
  One possible explanation of this difference in 
antigen handling by DC from risk variant and heterozygous groups is the structure of the processed 
antigens, requiring  a more complex degradation machinery for bacteria compared to the a soluble 
protein of dietary origin, such as ovalbumin. 
DC sampling of luminal antigens has been shown to occur under non inflammatory, steady state 
conditions, and is therefore thought to be involved in the maintenance of intestinal immune 
tolerance. In line with this, and with the finding that autophagy is involved in the degradation of 
30 
 
tight junction proteins, we showed that autophagy also regulates DC–epithelial interactions in the 
model system.
16
 Others have shown previously that DC form protrusions through the epithelial 
layer, and sample luminal antigen.
18
 We found that DC of patients carrying the T300A allele of 
ATG16L1 form less transepithelial protrusion through the Caco2 monolayer compared to wild type 
and heterozygous patients. In addition, it is known that autophagy deficient DC are also less capable 
of degrading pathogens sampled through the intestinal mucosa. 
19-20
 In line with these observations, 
we found that DC from risk children are less efficient in sampling bacteria particulate fragments 
when added to the apical side of the transwell filter in a co-colture system with Caco2 epithelial 
cells. Furthermore, upon bacteria mucosal load, these DC were highly impaired in upregulating DR 
and CD86, two key molecules for activating T cell-mediated immune response. 
In conclusion, our data indicates defects in DC antigen sampling and activation in pediatric CD 
patients carrying the T300A ATG16L1 allele. The fact that there are a number of autophagy 
stimulating compounds already in clinical practice, makes us more confident that this may be a new 
therapeutic option, and a viable pathway, for intervention in CD, in particular for those patients 
carrying one, or more, SNPs associated with the autophagy machinery  (approximately 40% of the 
total CD population) .
21 
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2.1.3 Authophagy Genes Variants and Pediatric Crohn’s disease phenotype: a single-center 
experience. 
 
The molecular basis of the pathogenesis of CD is not completely understood. Strong 
epidemiological evidence for a genetic predisposition has stimulated recent efforts to identify the 
susceptibility genes.
22-23
 In 1996 the discovery of NOD2/CARD15, the first gene identified to be 
associated to CD 
24
, represented one of the first success story in the genetics of a complex polygenic 
disease. Genome wide association studies (GWAS) have provided evidence for several 
determinants, including genes encoding ATG16L1 (autophagy-related 16-like 1) and IRGM1 
(immunity-related GTPase family M), providing further insights into disease pathogenesis.
25
 These 
genes are involved in a biological process known as autophagy, which plays a role in protein 
degradation, antigen processing, regulation of cell signaling, and many other pathways essential to 
the regulation of inflammation.
26
 Different studies found in pediatric patients a strong association 
between NOD/CARD15 SNPs and an early-onset disease as well as a major ileal or ileo-colonic 
localization of CD.
27-28
  However, regarding ATG16L1, a correlation between ATG16L1 risk allele 
and a more frequent ileal involvement of CD has been described in adults 
29
, but there are no 
evidences in children.  In addition, only one pediatric study 
30
 analysed the recurrence of IRGM1 
SPNs and CD risk, but no associations were found between these SPNs and the clinical course of 
the disease. The purpose of our study is to evaluate the relationship between the main risk alleles of 
NOD2/CARD15 (rs2066844; rs2066845; rs2066847), ATG16L1 (rs2241880) and IRGM1 
(rs13361189; rs4958847), and the clinical features in our cohort of children affected by CD.   
To our knowledge, this is the first pediatric study reporting an association between the presence of 
rs2241880 risk polymorphism of ATG16L1 in children with CD and a more severe phenotype of 
disease. We clearly demonstrated that patients carrying the homozygous risk allele show a 
significant trend to change from an inflammatory to a structuring behaviour. Hypothetically, the 
more severe phenotype may be somehow linked with the early development of fibrosis. In line with 
this phenotype, we demonstrated an association of rs2241880 risk polymorphism and the lack of 
perianal disease, suggesting that the ATG16L1 risk allele may exert a protective effect on the 
development of this manifestation in CD children. To support the hypothesis of worst phenotype in 
homozygous patients, we found that rs2241880 risk polymorphism was related to a major incidence 
of clinical relapses and with the introduction of immunosuppressants. In addition, children carrying 
rs2241880 risk allele show higher values of fecal calprotectin and CRP at diagnosis compared with 
patients carrying ATG16L1 heterozygous or wild type variants. Although, the role of fecal and 
serologic markers in predicting IBD disease course is still controversial, the hypothesis that higher 
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values at diagnosis could predict a more severe disease course has been claimed. Our data were 
strengthened by either a discriminant function, either a multivariate logistic regression analysis. 
Indeed, the multivariate logistic regression analysis demonstrated that development of structuring 
behaviour, followed by relapse during the first year of disease and absence of perianal disease, were 
respectively the most significant variables associated with ATG16L1 risk allele. In accordance with, 
Our data from functional studies are in accordance with these genotype-phenotype results, indeed 
we show that the monocyte-derived dendritic cells (DC) from pediatric patients with CD carrying 
the ATG16L1 risk polymorphism are impaired in the proper antigen sampling and processing. 
Furthermore, we found that DC from the risk group almost completely failed in upregulating the 
HLA-DR and CD86, the 2 key molecules for activating T-cells mediated immune response. Since 
intestinal microorganisms have been suggested to be one of the causes responsible of the bowel 
inflammation, it is likely that an alteration of autophagy process might lead to an uncontrolled 
microorganism growth in the intestine of IBD patients.
31
 The IRGM1 gene has been recently 
identified to play a role in the development of CD and also shown to be involved in autophagy.  In 
contrast, however, the extensive amount of work that has been accomplished in identifying and 
characterizing the complex network of ATG molecular mechanisms, there is much less known 
about the role of the IRGM1 related autophagic pathways.
32
 We found that the presence of IRGM1 
rs13361189 variant allele was associated with a lower use of immunosuppressant therapy, 
highlighting a possible role on the development of a milder phenotype. However, none of the 
associations were confirmed at the multivariate logistic regression analysis and further studies are 
needed to provide definitive conclusions about IRGM1 rs13361189.  Several studies supported the 
concept of more frequent small bowel disease in children and adolescents 
33,34
 and a significant 
association between ileal disease and the carriage of one or more NOD2/CARD15 variant alleles. 
According to the current evidences, our analyses of genotype-phenotype correlation showed that 
patients carrying the NOD2/CARD15 rs2066847 (1007fs) heterozygous allele had a more frequent 
ileal involvement than children showing the wild type variant for the same SNP. Our study has 
some limitations, including the small cohort of patients. However, the associations were confirmed 
with powerful statistical tests in order to avoid potential bias.  
In conclusion, we assume that genetic susceptibility may have a more important role in the etiology 
of pediatric-onset IBD. 
35-36
 IBD has certainly a multifactorial origin, and the importance of 
environmental is widely recognized. However, if genetic susceptibility is greater, than pediatric 
IBD patients can be expected to have a more severe clinical course of the disease. Within pediatric-
onset CD, specific genotype-phenotype associations can be found.  In our pediatric cohort, ATG16L 
homozygous risk allele resulted to be associated with a more aggressive disease course, including 
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development of structuring behaviour, early relapse and premature use of immunosuppressants.  As 
previously demonstrated, the presence of heterozygous allele of NOD2/CARD15, significantly 
correlated with major ileal disease. These data stress the importance of genetic susceptibility 
research in larger pediatric onset IBD cohorts in order to find new genes and to allow an early 
treatment stratification of these patients. 
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2.2 Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease 
 
Anaemia is the most frequent extra-intestinal manifestation of in ammatory bowel disease [IBD], 
with a great impact on the patient’s quality of life.37-38 
Hepcidin, a 25 amino-acid peptide mainly secreted by hepatocytes, controls the amount of iron 
entering the blood circulation by binding and downregulating ferroportin, a plasma membrane 
transporter that pumps iron out of phagocytes and duodenal enterocytes. The hepcidin expression is 
regulated transcriptionally in response to changing serum iron levels. Elevated serum iron promotes 
hepcidin expression, leading to downregulation of ferroportin and decreased entry of iron into the 
circulation.  
The role of hepcidin in the mechanisms of anaemia in paediatric IBD is limited and shows con 
icting results. Increased urine
39
or serum 
40 
hepcidin has been reported in two studies, correlating 
with the rise of IL-6 levels, ferritin, and disease activity. Conflicting results may suggest that 
hepcidin in human IBD is likely to be in uenced by various factors such as age, type of disease, and 
disease activity.  The primary aim of this study was to correlate hepcidin serum levels in patients 
affected by paediatric IBD with disease activity, in ammatory markers, and iron absorption. The 
secondary aims were to compare serum hepcidin levels of IBD patients with a group of coeliac and 
healthy patients, and to establish which iron parameter better correlates with hepcidin.  
To the best of our knowledge, this is the paediatric study evaluating iron absorption and serum 
hepcidin levels in IBD paediatric patients. Our data show that IBD children with active disease tend 
to have impaired iron absorption, driven through the hepcidin pathway. Indeed, serum hepcidin 
levels were signicantly higher in IBD patients with moderate to severe activity as compared with all 
other groups, including patients with mild activity or in remission, coeliac patients, and healthy 
controls. In addition, a signicant inverse correlation was found between hepcidin levels and iron 
absorption.  
Despite its relative high prevalence, costs, and impact on patient quality of life, it is rarely 
considered and adequately treated.
38,41,42
 In our study population, the prevalence of anaemia among 
IBD patients was 34%. The development of ACD is caused by numerous factors, among which 
hepcidin is now considered the leading actor. Indeed, the decrease in ferroportin expression, which 
results from elevated hepcidin levels, would block entry of iron into the circulation, with 
consequent erythropoiesis impairment. Furthermore, since intestinal absorption of iron is inhibited 
by downregulation of ferroportin on enterocytes, the anaemia would be resistant to oral iron sup- 
plementation.
43-44 
 Therefore, serum hepcidin may represent an useful surrogate marker to 
distinguish patients with impaired iron absorption in whom intravenous iron could be used as rst-
line option. Indeed, serum hepcidin may serve as a useful, sensitive, surrogate marker to distinguish 
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patients with impaired iron absorption in whom intravenous iron could be used as first line option, 
avoiding the waste of time with a futile and possibly harmful cycle of oral iron. Further studies are 
needed to better elucidate the role of hepcidin in both iron metabolism and in ammation in IBD, in 
order to design new therapeutic strategies for ACD in paediatric IBD.  
Though the etiopathogenesis of IBD is still unknown, it has been suggested that the interaction of 
environmental factors and host immune response with genetic individual susceptibility play an 
important role.
37
 Both human and animal studies have demonstrated the central role of intestinal 
microbiota in flaring up and perpetuating inflammation in IBD patients.
37 
IBD are associated with significant shifts in the composition of the normal enteric microbiota 
compared to control subjects, with an almost depletion of Lactobacillus and Bifidobacterium 
45
, 
normally present in healthy intestinal conditions, and increase of harmful species, such as 
Proteobacteria and Actinobacteria.
46
 This kind of dysbiosis might determine in the host organism 
the loss of tolerance towards microbes and induce an inappropriate inflammation.  
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2.3 Impact of Environmental and Familial Factors in a cohort of pediatric patients with 
Inflammatory Bowel Disease   
 
In the last years, epidemiological and molecular studies stressed the importance of genetic 
susceptibility in causing IBD onset.
47,48 
However, important features such as the significant 
geographical variation in disease incidence, the incomplete penetrance among monozygotic twins, 
and the striking rise of IBD  over the course of the past century, can’t be explained with genetic 
predisposition alone and reinforce the environmental hypothesis for IBD etiology. 
49-51 
 So far, in 
addition to familial aggregation, which is the most important IBD risk factor, only tobacco smoking 
and appendectomy have been demonstrated to be strongly associated with IBD incidence.
52-54
 
 An emerging and interesting theory supporting the environmental influence on IBD onset, is the 
“hygiene hypothesis”, which correlates the epidemiological rise in IBD incidence over the 20th 
century, both in developed and developing countries, with the improvement in general hygienic 
conditions (i.e. free access to clean water, smaller family size, etc.). 
55-57
 
Understanding the role of environmental factors is important not only for the possible preventive 
interventions in genetically predisposed individuals, but also to offer a better disease care to those 
already suffering with IBD.  Therefore, the purpose of our work was to investigate the relation 
between the exposure to some environmental factors and the risk to develop UC and CD in a cohort 
of pediatric patients in Southern Italy. 
Understanding the role of environmental factors is important not only for the possible preventive 
interventions in genetically predisposed individuals, but also to offer a better disease care to those 
already suffering with IBD. Therefore, the purpose of our work was to investigate the relation 
between the exposure to some environmental factors and the risk to develop UC and CD in a cohort 
of pediatric patients in Southern Italy. Our study suggests numerous evidences supporting the 
influence of environmental factors as possible explanation for the significant increase of IBD 
incidence in the last decades.
58
 To the best of our knowledge this is the first pediatric study 
addressing the hypothesis that the development of IBD may be related to a lower adherence to 
Mediterranean diet, assessed with a validated questionnaire. 
As previously reported, having a first degree relative with IBD represents the single most important 
factor determining an individual’s risk for developing the disease59, confirming the importance of 
genetic background. However the fact that environmental factors play a major role in IBD 
development is corroborated by many of our results. We confirmed that antibiotics areassociated 
with increased risk of CD.
60,61 
The use of antibiotics may alter the composition of the gut 
microbiome with the loss of potentially beneficial bacteria and the emergence of potentially 
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pathogenic bacteria.  Alternatively, the loss of immune interaction with potentially pathogenic 
bacteria at an early age fails to prime the immune system to harmful organisms that it may 
encounter later in life.
60,61
 Moreover, our study confirms an association between crowded housing  
and protection against the development of both IBD forms: owning pets, reduced number of toilets 
at home and higher number of siblings were associated with a lower risk for both CD and UC.  
Family size can be used to indicate the level of overcrowding in a home, which has been associated 
with potential exposure to infection. A small family size and thus a less propensity for exposure to 
infections have been associated with a higher risk for IBD.
62
 Siblings may influence the 
development of IBD altering exposure patterns to microorganisms in early life, affecting acute 
manifestation of infections, or influencing age of transmission and severity.
63
 
Above all, the striking difference in Mediterranean diet adherence, between cases and controls, has 
to be considered the most innovative finding of our study. Indeed, the Mediterranean diet is perhaps 
considered one of the healthiest dietary models currently existing. Numerous epidemiological and 
experimental nutrition studies have demonstrated how Mediterranean countries benefit from lower 
rates of chronic disease morbidity and higher life expectancy.
64
 There are several proposed 
mechanisms of action to explain the association between IBD and dietary choices. These proposed 
mechanisms involve a direct effect of dietary antigens, alteration of gut permeability, and the auto 
inflammatory response of the mucosa due to changes in the microbiota 
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2.4 Enterocytes and dendritic cells both contribute to the intestinal  inflammation in pediatric 
inflammatory bowel diseases.  
 
Gut inflammation occurring in patients with IBD is characterized by the infiltration and activation 
of either adaptive branch, as T and B lymphocytes, and innate system, as macrophages and dendritic 
cells, which in turn produce massive amounts of proinflammatory cytokines contributing to the 
typical mucosal lesions.
65-67
 It is well known that in CD cytokines released by T helper (Th)-1 cells 
are dominant, as interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin-12 (IL-12), 
whereas the Th2 cytokines, IL-5 and IL-13, are predominantly found in UC 
68
 However, in recent 
times several evidences have underlined the role of enterocytes  asnon immune inflammatory cells 
in the pathogenesis of IBD.
69
 Enterocytes have a pivotal role in maintaining the integrity of 
intestinal mucosa, and guarantee the gut homeostasis by sampling the luminal agents through the 
several receptors expressed on their surface.
70 
Therefore, the aim of our study was to evaluate the cytokine production profile and the activation 
status of both lamina propria and epithelium cell compartments through an ex vivo analysis of colon 
biopsies obtained from pediatric patients with IBD. 
Our ex vivo analysis of biopsies mainly obtained from the unaffected colonic area revealed an 
increased densities of cells producing TNFα in CD mucosa and IFN- in UC mucosa compared to 
control gut, although in both cases the percentage of positive cells was low and the differences were 
slight. Of note, we found a marked increase of cells expressing IL-15 in biopsies from both forms of 
IBD. Interestingly, when we determined the cell source of these pro-inflammatory cytokines by a 
multiparametric flow cytometry analysis, we found that both immune and nonimmune cells 
displayed an inflammatory phenotype in pediatric IBD intestine. EpCam+ enterocytes expressing 
IL-15, HLA class I and TNF-α were found more frequent in IBD compared to control biopsies. 
Moreover, in fresh intestinal tissues from both CD and UC young patients we observed a higher 
infiltrates of CD11c
+
 dendritic cells co-expressing TNF-α and the activation marker HLA-DR than 
the healthy mucosa, whilst CD11c
+
 DC producing INF- were more abundant in the gut of UC 
subjects. In steady state the biopsies from UC patients had an increased density of INF-+ T 
lymphocytes, whilst T cells producing TNF-α were prevalently found in the mucosal explants of 
both CD and UC patients.  
In conclusion, we demonstrated that in young subjects either immune competent cells, as T 
lymphocytes and dendritic cells, and nonimmune cells as enterocytes, have a pro-inflammatory 
phenotype in intestinal mucosa of pediatric cohort of patients with IBD. Our study underlines the 
relevance of gut epithelial cells as one of central mediators of mucosal inflammation in IBD. It is 
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becoming clearer that enterocyte has a role in intestinal mucosa much more active than it has been 
considered so far. Taking into account that intestinal epithelium cells represent a central node of 
mucosal cell networks, and that their dysfunction has been related with IBD pathogenesis, these 
cells could be a new therapeutic target for IBD. Indeed many studied reported that epithelial cells 
respond to TNF-α 71, and are a target of TNF-α inhibitors 72,73As prominent source of intestinal IL-
15 in IBD,  monoclonal anti-IL-15 antibodies
74
,or pharmacologic agents that can selectively block 
IL-15 signal transduction pathways, could be considered a new strategic target for biological 
therapies directed to these gastrointestinal diseases.
75
 However  further studies are needed to 
improve the  knowledge of the role of epithelial cells in IBD pathogenesis in order to better state  
the possible efficacy of epithelial cells-based therapeutic opportunities and their application. On the 
other hand, the marked rising in the incidence of IBD in childhood
76
, renders of particular interest 
such studies, evaluating ex vivo the phenotype and the cytokine profile of innate and adaptive 
immune cells in young IBD patients. Pediatric patients with IBD seem to be a distinctive population 
with specificities requiring highly skilled and specialized approach for diagnosis and treatment.
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Chapter 3. 
 
3.1 Synergistic effect of interleukin-10-receptor variants in a case of early-onset 
ulcerative colitis. 
 
A recent study has demonstrated that IBD with an early onset can be monogenic. Mutations in 
IL10 or its receptor lead to a loss of IL10 function and cause severe intractable enterocolitis in 
infants and small children.
1
 
IL10R consists of two α (IL10RA) and two beta (IL10RB) molecules. IL10RA and IL10RB 
genes have been mapped on chromosomes 11q23.3 and 21q22, respectively, and many single-
nucleotide polymorphisms (SNPs) have been identified.
2
 Recently, Moran et al identified 
IL10Rs polymorphisms that confer risk for developing very early-onset IBD.
3
 
The aims of this work were to clarify the molecular basis of UC in an 18-mo-old affected 
child. To this aim, we investigated the pathogenetic mechanisms of IL10 pathway alteration in 
the onset of UC in the proband, and we clarified the molecular changes associated with them. 
Moreover, we propose β-catenin and tumour necrosis factor α receptors-I (TNFRI) as 
molecular bio-markers of subclinical disease among apparently healthy family members of the 
index case. Finally, we have investigated the effect of mesalazine and azathioprine, the main 
pharmacological therapy used for IBD treatment, on the expression of IL10 receptors, TNFα 
and TNFα receptors. 
As suggested by Moran et al 
3
 and also described for other human diseases 
4
, our results 
confirm that early-onset IBD could be attributed to a synergistic effect of several variant 
alleles of the genes encoding IL10 receptors. These variants, alone, could only give rise to a 
sub-clinical manifestation of the disease. In fact, the proband’s father and his brother, both 
carriers of homozygous A/A polymorphism E47K for the IL10RB gene but without the -
413G->T promoter mutation in the IL10RA gene, were apparently not affected. The proband’s 
mother shows a genotype very similar to the proband. In fact, they are both heterozygous for 
the E47K IL10RB gene polymorphism and for the -413G->T promoter mutation in the 
IL10RA gene. Possibly due to the different IL10RA mRNA expression, the proband’s mother 
has not developed the disease. 
Unexpectedly, we observed β-catenin and TNFRI protein over-expression in the peripheral 
blood cells of the proband’s apparently healthy relatives more than in the proband himself. 
Therefore, we suggest that these proteins could represent a good candidate for molecular 
markers of sub-clinical disease in relatives of patients with UC. 
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Because no therapeutic approach was successful in patients who are carriers of IL10 pathway 
alterations, we investigated the effect of mesalazine and azathioprine on the expression of 
IL10 receptors, TNFα and TNFα receptors. In agreement with our hypothesis, we found 
TNFRI under-expression and TNFRII and IL10RB over-expression in primary fibroblasts 
incubated with mesalazine and azathioprine, in both the UC and FAP patients. In the UC 
patient only, azathioprine, but not mesalazine, induces a TNFα decrease. 
These observations could suggest that these drugs are only able to partially restore IL10 
pathway function in UC, by activation of IL10RB, but not IL10RA, transcription. On the other 
hand, under-expression of TNFRI and over-expression of TNFRII could increase the risk of 
colorectal cancer-associated colitis in UC patients. As described by Chang et al 
5
, TNFRI has 
tumour suppressor activity in the context of colitis-associated cancer, and the role of TNFRII 
in cell proliferation is well known. 
In conclusion, our results, in agreement with data from recently published literature
6,3,4
, 
indicate that early-onset UC could be caused by a synergistic effect of more variant alleles of 
the IL10 receptors gene, resulting in alteration of the IL10 pathway. In our opinion, a dosage 
model of nonallelic non-complementation fits well with this case, whereby mutations in two 
different genes can behave as alleles of the same locus by causing or exacerbating the same 
phenotype. However, we cannot exclude, as described for others syndromes, that different 
mechanisms, such as alternative splicing mechanisms
7,8
or allelic variants of modifier genes, 
could contribute to the observed phenotypic variability.
4
 
In addition, we suggest that the expression of β-catenin and TNFRI protein could represent 
molecular markers of sub-clinical disease in apparently healthy relatives of patients. Recent 
findings suggest that chronic inflammation in IL10-/- mice increased P-β-catenin expression. 
Moreover, TNFRI exerts its tumour suppressor activity by modulating activation of β-catenin 
and controlling epithelial proliferation.
9
 It clearly appears that classical therapeutic approaches 
do not seem adequate for IBD patients who are carriers of IL10 pathway alterations because 
under-expression of TNFRI signalling would confer increased risk of developing colitis 
associated-carcinoma. Allogenic hematopoietic stem cell transplantation could represent a 
causal therapeutic approach for IL10R-deficient patients, useful for the treatment of the 
intractable ulcerating enterocolitis of the infant, as recently suggested.
1,2,10,4 
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3.2 Cannabinoid receptor 2 functional variant contributes to the risk of pediatric 
inflammatory bowel disease 
 
The endocannabinoid (EC) system has been recently indicated as a possible therapeutic target 
in IBD. 
11,12
 
 The EC system includes the EC endogenous lipid transmitters, their G-protein-coupled 
cannabinoid receptors type 1 and 2 (CB1 and CB2), and the enzymes for EC metabolism. ECs 
are synthesized and immediately released “on demand”, although they can also accumulate in 
intracellular adiposomes .
13
 
Common variant, rs35761398 (CAA/CGG), of the CNR2 gene, encoding for the CB2 
receptor, is associated to autoimmunity unbalance. 
14,15
 
In particular, the presence of the arginine (R) at codon 63 significantly reduces the EC-
induced inhibition of lymphocyte proliferation, suggesting the R variant as the less 
functional.
14
 
This less functional variant CB2-R63 has been associated with increased risk of chronic 
immune thrombocytopenic purpura and celiac disease, in childhood. 
16,17
 
We conducteda case-control association analysis between  the common CB2-Q63R functional 
variant and IBD in a cohort of 221 Italian children with IBD comparedto 600 controls 
previously recruited from the same geographic area. Moreover, we evaluated possible 
correlations between the CB2-Q63R variant and the clinical features of our pediatric IBD 
patients. 
We describe, for the first time, the association between the CNR2 rs35761398 polymorphism 
(CB2-Q63R variant) and the risk of pediatric UC and CD. Of note, we also found an 
association between the aforementioned SNP and specific clinical CD and UC sub-
phenotypes. Taken together, our data highlight the involvement of CB2 in the pathogenesis of 
pediatric IBD and provide insight into its possible role inthe clinical features of chronic 
intestinal inflammation. We found that the GG/GG genotype (RR homozygous subjects) was 
highly prevalent in IBD children. Interestingly, when CD and UC patients were analyzed 
separately in comparison with controls, a significant over-representation of the RR genotype 
and of the R allele was observed for the CD children. 
This finding is in line with the fact that ECs produce a bias in the balance between the two 
types of Th cells, suppressing Th1 and enhancing Th2, and that the CB2-Q63R variant 
isinvolved in this process exerting a different inhibition of these cells according to the 
presence of Q or R 20. This bias has several mechanisms. It has been partly explained by 
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different expression of cannabinoid receptors on subpopulations and on antigen-presenting 
cells. It could be due to modulation of cytokines generated by dendritic cells. 
18
 
 In addition, the induction of Th2 associated cytokines can after wards inhibit Th1cells. 
19
 
Recentdata show that ECs, via CB2 receptor, can directly induceB-cell class switching from 
IgM to IgE in favor of a Th2 type immunity. 
20
 
Therefore it is reasonable that this CB2 variant, which has been related to decreased 
immunomodulatory response and the development of autoimmune disease
14
, is mainly 
associated with a Th1-mediated disease, such as CD. 
Indeed, in many previous studies, cytokine profiles of CD patients displayed Th1 dominance 
characterized by higher levels of IFN-γ and TNF-α and lower amounts of IL-4 in the intestinal 
mucosa and serum of CD patients compared with healthy controls. 
21,22
 
Finally, it has been suggested that a shift towards the Th1 profile may contribute to the onset 
of CD by activating macrophages, which produce pro-inflammatory cytokines causing 
intestinal damage. 
23
 
In both CD and UC children, the R63 variant was strongly associated with moderate to severe 
activity of the disease calculated with PCDAI and PUCAI score, respectively. Moreover, in 
UC patients, the CB2-R63 variant was associated also to a higher incidence of early clinical 
relapse, further suggesting an association with a  more severe phenotype of disease. Indeed, an 
impaired functionality of CB2 receptor could determine a decreased suppression of activated 
macrophages and mast cells and stimulate the secretion of pro-inflammatory cytokines such as 
TNF-α 24,25, causing an exacerbation of intestinal inflammation and worsening disease course. 
The marked rising in the incidence of IBD in childhood
17
, renders of particular interest our 
study since in a paediatric population with IBD the genetic susceptibility could be greater and 
influence a more severe disease course.The present results also support the concept that the 
CB2 receptor on immune effector cells may represent a potential molecular target for selective 
CB2 agonist therapies that could suppress autoreactive, pro-inflammatory innate and adaptive 
immune responses.Further investigation as well as targeted functional studies are needed to 
understand how Q63R genotype contributes to disease susceptibility in pediatric IBD, and 
whether presence of these polymorphic markers might have clinical therapeutic implications. 
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3.3 Genetic sharing and heritability of paediatric age of onset autoimmune diseases. 
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3.4  Meta-analysis of shared genetic architecture across ten pediatric autoimmune 
diseases. 
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Inflammatory bowel disease (IBD), characterized by chronic, relapsing immune-mediated 
inflammation of the gastrointestinal tract is often associated with extra-intestinal manifestations 
(EIMs) affecting multiple organs. EIM are reported to occur in 18–47% of paediatric and adult 
patients with IBD. 
1-5
Acute and chronic pancreatitis as well as pancreatic insufficiency have been 
reportedas one of EIMs in IBD.
6
There are only limited published dataon the incidence of acute 
pancreatitis in paediatric patients with IBD. 
7,8
 
Despite scattered case reports, the relationship between pancreatic involvement and IBD has not 
been further investigated. The primary aim of our study was to investigate prevalence and  disease 
course of paediatric IBD patients presenting with pancreatitis; secondary aim was to evaluate the 
clinical significance of  exclusive hyperamylasemia and hyperlipasemia in children with IBD. 
To the best of our knowledge our paper represents the first paediatric multicentre IBD registry-
based study, characterizing the natural history of pancreatic involvement. Consistent with the 
published literature in the present cohort, the prevalence of pancreatic involvement was 4.1% and 
acute pancreatitis was diagnosed in 1.6% of cases. 
The question of whether pancreatitis is an EIM of IBD remains unclear.
9
The aetiology and 
pathogenesis of AP (acute pancreatitis)  are elusive and seem to be multifactorial in themajority of 
IBD patients. It is possible that epithelial cells of the gastro-intestinal tract and pancreatic tissue, 
may share similar target molecular or cellular structures vulnerable to injury. To support this 
hypothesis in our cohort ofpatients acute pancreatitis was present at IBDonset in 18%, suggesting 
that in somecases pancreatic dysfunction is part of a common immune disorder. 
As previously described in paediatric literature, in our study AP incidence was not different 
according to the IBD type, either CD or UC.
7 
Moreover according to Heikius et al. who 
demonstrated a correlation between the lipase increase and the histological activity of the disease, 
91% of our patients with pancreatic involvement presented active disease.
6
 Furthermore, patients 
with recurrent episodes of AP and hyperamylasemia/hyperlipasemia showed higher PCDAI/PUCAI 
scores at 6 and 12 months. These data may suggest that pancreatic involvement could be strictly 
related to the activity of disease at least in a 320 subset of patients.  
Chapter 4  
 
4. Peculiar clinical features in inflammatory bowel disease  
 
4.1 Natural history of pancreatic involvement in paediatric inflammatory 
bowel disease. 
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Interestingly, the majority of our patients with CD and AP showed a colonic involvement, as 
previously described.
7
 Nevertheless, It is well known that paediatric patients with CD present with 
more colonic involvement.
10
 The association between colonic disease and AP remains obscure. One 
possible explanation may be that the colon is considered a major source of the bacteria causing 
pancreatic necrosis in AP. Supporting this hypothesis subtotal colectomy before AP in rats was 
found to reduce mortality. 
Finally female gender resulted to be significantly associated with the onset of pancreatitis in our 
patients, also when comparing with the total IBD registry population. Female predominance in the 
majority of autoimmune disorders may be one of the possible explanations. 
Our study has some limitations besides the retrospective nature. Firstly, we did not have a control 
group of patients with AP without IBD; second, we did not evaluate serological markers of 
autoimmune pancreatitis. One could argue that the number of IBDpatients with pancreatic 
involvement is too small to draw definitive conclusions; furthermore, in this subset of patients it is 
difficult to clearly define the aetiology of AP, as IBD itself is a predisposing factor, and 
development of pancreatitis is certainly multifactorial. 
Nevertheless our data, based on a large paediatric IBD population, highlight once again that 
pancreatic involvement has a relatively low prevalence. However, a specific attention has to be paid 
to the monitoring of pancreatic function IBD children, considering that in a proportion of patients 
the pancreatic involvement tends to persist and in some cases pancreatic damage may evolve. 
Future studies on the pathogenesis of pancreatitis and its relationship to the long-term outcome in 
IBD are required. 
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4.2 Clostridium difficile and Pediatric Inflammatory Bowel Disease: A Prospective, 
Comparative, Multicenter, ESPGHAN. 
 
The prevalence of C. difficile infection in pediatric patients with IBD is reported over a broad range 
from 3.5% to 69%.
11-16 
 Indeed, despite considerable advances in understanding the epidemiology, 
immunology, and pathogenesis, Clostridium difficile (C. difficile) infection is still the most frequent 
cause of nosocomial bacterial infectious diarrhea in developed countries. 
17
 
Most of our current knowledge stemsfrom studies in adults with numerous confounding factors. 
Despite the association with pediatric IBD, data regarding the health care burden related to C. 
difficile infection in children withIBD are limited to few studies. The primary aim of our study was 
to investigate the occurrence of C. difficile infection in pediatric patients with IBD and to compare 
with a group of children affected by celiac disease; secondary aim of this study was to evaluate 
natural history and disease course of C. difficile infection in pediatric patients with IBD. 
To the best of our knowledge, this is the first prospective, multicenter pediatric study characterizing 
the occurrence and natural history of C. difficile infection/colonization in patients withIBD. We 
found that although infection is common in certain countries and rarer in others, it seems to be 
associated with approximately 15% of relapses. Clostridium difficile infection was significantly 
higherin patients with IBD than patients with celiac disease. We decided to test patients with celiac 
as control group, to verify whether another gastrointestinal pathology with described microbiota 
alterations, such as celiac disease, may confer a higher susceptibility to C. difficile infection. Our 
data confirm that C. difficile increased risk is related to IBD itself. 
In addition we found that there was no specific IBD type predisposing to C. difficile colonization. 
This is consistent with published pediatric literature.
18,19
 Our data seem to indicate that colonic 
involvement rather than disease type is the explanation for the association with UC. Most patients 
with IBD with C. difficile in our cohort (85.7%) showed colonic involvement, independent of the 
type of disease, as previouslyreported.
20
 In agreement with previous articles, C. difficile was 
mainly community-acquired.
11-16
 This is a further warning that C. difficile epidemiology is 
changing, and classical risk factors are often not involved. 
Aside from disease location, other traditional risk factors seem to be less important or have no 
association with pediatricIBD. We could not demonstrate that medications such as PPIs or immune 
modulators were associated, and hospitalization did notincrease the risk for acquiring C. difficile. 
In conclusion, this prospective, multicenter study confirms that pediatric IBD is associated with 
increased C. difficile detection.Clostridium difficile is associated with a severe disease course, as 
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demonstrated by the escalation of immunosuppressive therapy, the higher frequency of active 
disease, the colectomyrate, and the higher number of hospitalizations at 6 months. 
A consistent number of patients show an asymptomatic carriage, which should be carefully 
evaluated, considering the possibility ofa quick worsening of disease. Future studies will clarify 
whether C. difficile has a causative role on IBD course exacerbation or if may simply colonize 
those patients with a more severe phenotype. 
In addition, the relationship between C. difficile and IBD pathogenesis should be further 
investigated. 
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4.3 Periappendiceal Inflammation in Pediatric Ulcerative Colitis  
 
It is classically accepted that inflammation in ulcerative colitis (UC) originates in the rectum and 
spreads in continuity to the proximal portions of the colon.
21
 
However, the proximal colon, especially at the base of the appendiceal orifice, is fre- quently 
involved by inflammatory infiltrates in patients with UC.
22
 
Several prospective and retroprospective studies have confirmed that periappendiceal inflammation 
(PAI), both endoscopically and histologically, is common in UC.
22,23,24
 
Only one pediatric study
25 
looked at PAI involvement in children who required colonic resection. 
The purpose of our prospective study was, therefore, to evaluate, by endoscopy and histology, the 
prevalence of PAI in children affected by UC.  
In this study, we found that PAI was endoscopically present in 32% of pediatric patients affected by 
UC not extending beyond the hepatic flexure. PAI was more frequent in children with new 
diagnosis of UC than in patients with pre-existing UC. In our study PAI seems to be related to the 
extent of diseaseWe can speculate that in pediatric patients, the disease is more extensive as 
reported by Van Limbergen et al,
26
who defined the phenotypic characteristics of pediatric UC. They 
found that children were more often affected by pancolitis and suggested a more severe phenotype 
in children than in adults. In our population, even if we ruled out children with pancolitis, we found 
that immunosuppressive use was significantly more common in children with PAI. This, in 
agreement with Van Limbergen’s finding, suggests a more severe pediatric UC clinical picture, 
irrespective of the presence of pancolitis.
27
 
We also found that clinical activity and the use of medical therapy were not involved in PAI.  
However, PAI, in our patients, was significantly more frequent in newly diagnosed children. 
Whether this finding is related to the efficacy of the medical treatment or to the natural history of 
pediatric UC needs to be further evaluated.  
At index colonoscopy, we found that the histologic grade of inflammation at the ascending colon 
was statistically higher in children with PAI. This higher grade of inflammation suggests that PAI 
may be representative of histologically active disease in the endoscopically unaffected proximal 
colon, although this involvement does not seem to contribute to clinical activity. Evidently, 
colonoscopy alone is unreliable for determining the extent of UC.
28
 
The higher histologic grade in the group A in the ascending colon suggests that the PAI may be a 
hallmark for subclinical active disease, identified by histology. The histologic involvement at the 
ascending colon, even in the presence of macroscopically normal mucosa, suggests that the number 
of pancolitis in children is higher than observed only by endoscopy.  
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This study has some limitations. We did not include the findings on colonoscopy re-evaluation at 
follow-up because currently we do not have enough data. It is known that there is a little chance in 
the pediatric studies to scope all children as planned, in particular when they are on remission. In 
addition, we do not provide details on follow-up because its duration in most of the patient is too 
limited.  
The importance of this study is that it is the first pediatric prospective study having the aim to 
define the features of UC with PAI that can be confused with Crohn’s disease. In fact, the occa- 
sional patchy areas of mucosal inflammation often left to a change of diagnosis to Crohn’s disease. 
Such a change in diagnosis from UC to Crohn’s disease can affect management decision, especially 
in regard to surgery.
29
 
In conclusion, to the best of our knowledge, this is the first pediatric study reporting the presence of 
PAI in children affected by UC not extending beyond the hepatic flexure. PAI seems to be more 
frequent in newly diagnosed children than in those with pre- existing diagnosis of UC, related to the 
extension of the disease and to an higher grade of histologic inflammation at level of the ascending 
colon.  
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Chapter 5 
 
5. New therapeutic strategies in inflammatory bowel disease. 
 
5.1 Bifidobacteria Enhance Antigen Sampling and Processing by Dendritic Cells in Pediatric 
Inflammatory Bowel Diseas 
 
In the last years, probiotics have bee tested as treatment agents for induction of remission in IBD, 
however the outcome of their use in clinical practice has not always been so encouraging
1
.  
The Bifidobacteriahave been largely studied among the probiotic species for their specific 
immunoregulatory effect on epithelial cells, lymphocytes and, above all, on DCs
2
.  
A recent study conducted in patients with IBD indicated that oral administration of Bifidobacterium 
sub- species have the capability of reducing inflammation in UC, through the increase of regulatory 
T cells, and reduction in the serum level of inflammatory markers, such as tumor necrosis factor 
(TNF)-α, IL-6, and C-reactive protein.3 However, no experimental studies assessing the role of 
Bifidobacterium strains on DC maturation and functionality are available in either adult or pediatric 
IBD patients. In the current study, we aimed to analyze the effects of a mixture of 3 
Bifidobacterium strains (B. longum, B. breve, B. infantis), on the phenotype and on antigen 
processing of monocyte-derived DCs in a pediatric cohort with IBD.  
In this study, we demonstrate that a commercial probiotic mixture (Tribif) composed by 3 
Bifidobacteria species (B. longum, B. breve, and B. infantis) is able to ameliorate the impaired 
ability of antigen sampling and processing by DC from pediatric patients with CD. We found a 
marked reduction in the uptake of cellular fragments from the Enterobacteria E. coli by DC from 
children with CD, compared with both DC from either UC or non-IBD children. DCs from patients 
with CD were also impaired in processing soluble antigens, as shown by reduced intracellular 
degradation of the dietary protein ovalbumin. These results confirmed a defect of particulate antigen 
sampling in specialized antigen presenting cells from patients with CD, likely due to an impairment 
of autophagy, as we previously reported
4
. 
Interestingly, the probiotic mixture had no significant effect on the antigen uptake in DC from 
patients with UC, in which the autophagy functionality is not impaired as in CD. This difference in 
antigen handling is probably due to the different molecular pathway at the base of the pathogen- 
esis of these 2 intestinal diseases
5
. 
The beneficial effect on DC functionality reported in our study is a specific property of the 
probiotics, since the Enterobacterium Salmonella had an opposite effect, reducing significantly the 
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sampling efficiency of the DC. Moreover, we found that Tribif ameliorate the antigen phagocytosis 
and processing without enhancing the DC maturation or inducing a cytokine production. In 
particular, the proinflammatory TNF-α, which was significantly enhanced on the stimulation of 
particulate antigens from the Enterobacterium E. coli, was not induced in DC cell supernatant after 
the treatment with the BifidobacteriaTribif. This finding indicates that DC from children with CD 
are sensitized to produce TNF-α, an important player in CD pathogenesis, in response to specific 
bacteria strains
5
.Most current probiotics are marketed as foods or supplements that improve gut 
health and were developed based on ease of production or stability, rather than based on specific 
mechanisms of disease prevention or treatment. Many commercial probiotics have limited purity 
and viability making difficult conclusions about efficacy in the treatment or prevention of disease
6
. 
“Second generation probiotics” may be a useful term to describe probiotics selected based on 
established mechanisms of prevention or treatment of a specific disease. Bifidobacteria would fit in 
this category, suggesting mechanistic advantages compared with other probiotics.
7
Studying 
Bifidobacteria and other probiotics for metabolites and ligands that modulate the host immune 
function will likely lead to a new class of immunotherapeutic agents for inflammatory states.  
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5.2 Does cow’s milk protein elimination diet have a role on induction and maintenance of 
remission in children with ulcerative colitis? 
 
Food sensitivity/intolerance has been suggested to play a role in the aetiology of IBD, and the 
culpable foods vary on an individual basis. The most common behaviour resulted the avoidance of 
milk and dairy products; this dietary change resulted in reduced calcium intakes but had no apparent 
effect on the rate of relapse
 8
. On the other hand, malnutrition is very common in children with 
IBD.
9
The origins of malnutrition in IBD are multifactorial, but dietaryrestrictions (due to 
intolerance of diet or therapeutic fasting) are considered to be relevant.
10
Without further evidences, 
and considering the nutritional issues, it remains unclear whether dietary manipulation will continue 
to have a role solely in symptom control, or whether completeremission may be possible using these 
methods in combination with pharmacological agents. 
The purposes of this study were to evaluate the efficacy of a cow’s milk protein (CMP) elimination 
diet on induction and maintenance of remission and to define the association 
with atopy in children with ulcerative colitis (UC). This was a prospective, single-centre, 
randomized, controlled, 1-year study of children with newly diagnosed UC. 
In this study, we did not demonstrate a significant efficacy of CMP elimination diet in the induction 
and maintenance of remission in paediatric active UC. Patients receiving CMP elimination diet and 
concomitant conventional therapy did not have a significantly higher rate of remission compared to 
children on free diet with not significantly lower incidence of relapse within 1 year of follow-up. 
The belief that dairy products can exacerbate the disease and that patients restrict their consumption 
has already been documented.
11
However, several reports have demonstrated that inadequate caloric 
intake is the primary cause of growth retardation in IBD.
12,13
All clinicians should be aware that 
iatrogenic dietary restrictions, which are often imposed without a sound scientific or clinical basis, 
further reduce the amount of caloriesprovided, contributing to the malnutrition and various 
micronutrient deficiencies in paediatric IBD patiens.
14
Analysing the different therapeutic subgroups 
(steroids and mesalazine vs. mesalazine alone) within 1 year of follow-up, we found a higher 
incidence of relapses inpatients under steroid therapy of both CMP and free diet groups compared 
with patients treated with mesalazine alone. This finding clearly highlights that neither steroids nor 
CMP elimination diet were able to modify the natural history of the disease. Patients eligible for 
steroid treatment, and therefore with the worst onset of disease, continue to act with the same severe 
phenotype despite a more aggressive therapy . 
An important limitation of our study is the small number of patients. Because we had negative 
results (i.e., we did not find a statistical difference), and the sample size of thecohorts is somewhat 
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small, it is likely that the lack of significant difference occurred by chance. However, because there 
are no trends towards significance, we doubt that there is the risk of a type II statistical error in our 
study. 
Therefore, we believe that CMP elimination diet does not appear to be useful in the therapy of UC 
of children. 
In conclusion, data of this paediatric, randomized trial suggest that CMP elimination has no role in 
the management of UC in non-sensitized children. Further larger studies are needed to evaluate the 
efficacy of the CMP exclusion diet on the induction and maintenance of remission 
in UC atopic children. 
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5.3 Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the 
ESPGHAN Paediatric IBD Porto Group  
 
Biological medicines are complex protein-based compounds derived from a biological source as 
defined by the European Medicines Agency (EMA) .
15
 These proteins have a much larger molecular 
structure than the standard pharmacological preparations. When such small molecule drugs’ patents 
expire, generic products are introduced. Because of both their structure and biological activity, 
however, the counterpart of generics in terms of biologicals is called biosimilars.
15
The World 
Health Organization has defined these as ‘‘a biotherapeutic product which is similar in terms of 
quality, safety and efficacy to an already licensed reference biotherapeutic product’’.16 Because of 
the structure of the biological molecules and trade secrets of the companies producing the original 
products, the new versions are very similar but not exactly identical to the originator drug.  
Agencies including the US Food and Drug Administration (FDA) and EMA decided that for 
biosimilars, documentation of efficacy is not needed for all of the indications of the original 
molecule. Extrapolation may be acceptable provided that the pharmacokinetic (PK) and 
pharmacodynamic properties have been demonstrated in studies of all levels (in vitro, animal 
models, and clinical trials) in some of the indications.
17
 Because biosimilars have now come to the 
market in some countries, an overview is given on behalf of the paediatric inflammatory bowel 
disease (IBD) Porto group on the use of biosimilars in paediatric IBD (PIBD). The PIBD Porto 
group is a group of PIBD experts from European Society for Paediatric Gastroenterology, 
Hepatology, and Nutrition whose goals are to generate collaborative international research and to 
provide a leadership role with regards to current diagnosis and management of IBD in children. 
Children with IBD on average have a more severe disease phenotype than in adult-onset IBD, 
potentially requiring antitumour necrosis factor (anti-TNF) treatment for even longer duration. 
Therefore, in addition to the European Crohn’s and Colitis Organisation position statement on the 
use of biosimilars in the treatment of IBD, we hereby provide consensus-based recommendations 
specifically for paediatric gastroenterologists treating children with IBD.
18
 
It appears that the experience so far with the introduction of biosimilar therapeutic mAb is 
encouraging with regards to drug safety and effectiveness in rheumatology. Even minor alterations, 
however, in the production process of biologics may lead to changes in cell behaviour and cause 
differences in structure, stability, or other quality aspects of the end product, commonly because of 
differences in glycosylation patterns. Any of these differences may affect the treatment’s safety, 
efficacy, and, most importantly with biologics, the immunogenicity.
19
 In children, the risk of 
developing immunogenicity to anti-TNF treatment is even more worrisome than in adult patients 
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because children both have more severe disease and potentially need anti-TNF treatment for a 
longer period.  
Moreover immunogenicity is clinically a very relevant phenomenon with both IFX and 
adalimumab, and affects anti-TNF drug levels and clinical efficacy in both Crohn disease and 
ulcerative colitis.
20-27
 Therefore, there is no guarantee that our understanding of immunogenicity of 
the originator biological will easily be extrapolated to the biosimilar that may be subtly different in 
molecular structure. New assays need to be developed and studies undertaken to explore and 
understand the immunogenicity of the biosimilars.  
Concerns remain about the introduction of biosimilars, particularly in PIBD. These concerns should 
spark debates in the medical arena, and this information should be available to physicians who have 
to make the decisions about the welfare of their patients. In contrast, the introduction of biosimilars 
to the market will likely decrease the costs of anti-TNF drugs by 30%, thereby lowering the 
threshold of use of these highly effective but expensive drugs in IBD.  
Altough the Porto IBD group conclude with the following statement: 
The European Medicines Agency approved the use of biosimilars for infliximab for all indications, 
including adult and paediatric inflammatory bowel disease (IBD). The European Society for 
Paediatric Gastroenterology, Hepatology, and Nutrition paediatric IBD Porto group advocates 
giving high priority to performing paediatric trials with long-term follow- up to support this 
decision  
Treatment of a child with sustained remission on a specific medication should not be switched to a 
biosimilar until clinical trials in IBD are available to support the safety and efficacy of such a 
change. 
Postmarketing surveillance programs for efficacy, safety, and immunogenicity in children with IBD 
should be a manda- tory requirement for the marketing of biologics and biosimilars with respective 
indications.  
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6. Conclusion 
 
There is no doubt that we have achieved a big progress in the understanding of IBD pathogenesis  
during the past few years. IBD arises from an extremely complex interaction among genetic and 
environmental elements, dysregulated immune responses and alterations of the microbiome, and 
none of these factors alone is likely to cause the disease. More detailed information on their 
composition, function, and interaction is becoming increasingly accessible through high genomic 
approaches, investigation of environmental changes, molecular analysis of gut bacteria flora. Future 
research needs to further clarify the mechanisms and pathways of how bacteria, viruses or even 
fungi can modulate innate and adaptive immune responses. 
A true understanding of IBD pathogenesis is mandatory to improve current therapeutic approaches 
to IBD. There is no doubt that there has been an enormous improvement in the management of IBD, 
however results are far from ideal, particularly in regard to rather predictable recurrence of disease.  
As suggested from Fiocchi et al.
1
 probably one of the reason why previous drugs fail to work is 
because they essentially target exclusively the immunome, with disregard of the other components 
of IBD pathogenesis: the exposome, the genome, and the gut microbiome. Since IBD is the result of 
a complex integration of different components, an effective therapy can only be achieved if an “IBD 
integrome” approach is implemented. Individual approaches in IBD are impractical, but a 
comprehensive approach, like the one that systems biology can offer, seems reasonable. Biobanking 
is now a reality in all major medical centers, as well as in our center, and it allows the collection of 
large amounts of molecular data from genomic, proteomic, and microbiomic arrays. The 
combination of these molecular data generate models that can improve patient classifications, 
predict clinical course, select the most logical treatment forms, and anticipate 
outcome. 
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